Takaki, Shintaro <br/><br/>
Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial.  [electronic resource] 

 -  Intervirology  2007 
 - 439-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1423-0100 
<br/><br/><label>Standard No.: </label>10.1159/000114718  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anemia--chemically induced<br/>Drug Therapy, Combination<br/>Eicosapentaenoic Acid--pharmacology<br/>Female<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Prospective Studies<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage